These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18790953)

  • 1. The role of novel drugs in multiple myeloma.
    Dimopoulos MA; Kastritis E
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii121-7. PubMed ID: 18790953
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib and lenalidomide effective in myeloma.
    Cancer Biol Ther; 2007 Jan; 6(1):5. PubMed ID: 17612004
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed and refractory myeloma.
    Kaufman J; Gleason C; Lonial S
    Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A third-generation IMiD for MM.
    Cavo M
    Blood; 2011 Sep; 118(11):2931-2. PubMed ID: 21921051
    [No Abstract]   [Full Text] [Related]  

  • 7. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on drug combinations for treatment of myeloma.
    Srikanth M; Davies FE; Morgan GJ
    Expert Opin Investig Drugs; 2008 Jan; 17(1):1-12. PubMed ID: 18095914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
    Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
    Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
    [No Abstract]   [Full Text] [Related]  

  • 12. Frontline treatment of multiple myeloma.
    Fonseca R
    Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "IM iD"eally treating multiple myeloma.
    Lacy MQ
    Blood; 2013 Mar; 121(11):1926-8. PubMed ID: 23493767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
    Usmani SZ; Sexton R; Hoering A; Heuck CJ; Nair B; Waheed S; Al Sayed Y; Chauhan N; Ahmad N; Atrash S; Petty N; van Rhee F; Crowley J; Barlogie B
    Blood; 2012 Aug; 120(8):1597-600. PubMed ID: 22674807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
    Takeda Y; Sakaida E; Nakaseko C
    Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Islam A; Ambrus JL
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel agents for multiple myeloma treatment.
    Ribatti D; Vacca A
    Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
    Szturz P; Adam Z; Klincová M; Feit J; Krejčí M; Pour L; Zahradová L; Vašků V; Hájek R; Mayer J
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):517-20. PubMed ID: 21856265
    [No Abstract]   [Full Text] [Related]  

  • 20. Transplants for the elderly in myeloma.
    Morgan GJ
    Blood; 2013 Aug; 122(8):1332-4. PubMed ID: 23970352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.